Josh Bowen

Josh Bowen asked about the overall contribution of earlier treatment, increased combination use, and more patients making it to maintenance therapy towards achieving the 6-12 month duration range for Revuforj in 2026.

Answer

Michael Metzger, Chief Executive Officer, explained that growing combination use (currently around 40%) and earlier treatment lead to better patient outcomes and longer drug duration. He noted that combinations become even more important as they approach frontline treatment, where Revuforj has extensive data and has shown good tolerability and efficacy.

Josh Bowen asked how earlier patient capture, increased combination use, and more patients reaching maintenance therapy contribute to the projected 6-12 month average treatment duration for Revuforj in 2026.

Answer

Michael Metzger, CEO, noted that combination use is growing to about 40% of patients, which, along with earlier treatment, leads to better patient outcomes and longer drug duration. He emphasized that combinations are crucial as the company approaches frontline treatment, where Revuforj has extensive data and good tolerability.